Abstract
Prostate cancer (PCa) is the second most frequently diagnosed cancer in Brazil. Serum prostate specific antigen (PSA) is currently used for early detection of prostate cancer, however it lacks in specificity especially in Benign Prostatic Hyperplasia (BPH). Besides, it has limited accuracy to determine poor prognosis or drug resistance conditions. A growing body of evidence supports cruci…